FDA Grants Fast Track Designation for Nacuity’s Pill Treatment for Retinitis Pigmentosa
January 22, 2025

FDA Grants Fast Track Designation to Oral Treatment for Retinitis Pigmentosa

Nacuity’s NPI-001 investigational mutation-agnostic oral tablet therapy for retinitis pigmentosa has been greenlit for speedier approval by the FDA. The…

Nanoscope Therapeutics 02
October 10, 2024

Nanoscope Therapeutics to Submit BLA for Retinitis Pigmentosa Gene Therapy Candidate MCO-010

Sparked by new 100-week data and discussions with the FDA, the company’s bid for approval in the United States will…

Discover our fascinating content at issuu

explore